Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa + Radiotherapy in Head & Neck Cancer
NCT00233636Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Primary endpoint: Tumour Response Rate (CR + PR) at 6 months. Planned start Jul 2003; status: withdrawn.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00233636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233636.